Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.